Seminal
The magazine and atlas of EU-funded researchA new publication from the web and AI team at Scott Charnley

Atlas / Netherlands

Research and Innovation Action · Running

Hypermarker Personalised pharmacometabolomic optimisation of treatment for hypertension

Coordinator
Universitair Medisch Centrum Utrecht, Netherlands
Runs
1 January 2023 to 31 December 2026
Status
Running
EU funding
€8.0m
Total cost
€8.0m
Partners
13 organisations in 5 countries
Type
Research and Innovation Action
Grant agreement
101095480

What the project is doing

In the project's own words, from its summary on CORDIS.

Hypertension, or high blood pressure (BP), is a serious medical condition, and the single biggest contributor to circulatory diseases which continue to dominate as the leading cause of death and morbidity across the EU. It accounts for almost 10 percent of all healthcare-related costs. Systolic hypertension leads to a broad variety of diseases with an immense impact on both patients and healthcare systems. HYPERMARKER will unleash the potential of pharmacometabolomics to provide a ‘smart’ prescription of antihypertensive therapy.

Well-phenotyped cohorts from eleven European countries will provide metabolomic profiles and blood samples for pharmacometabolomic assessments to identify predictors of treatment response in hypertension using advanced AI and deep learning methods. Prediction models for individual treatment responses to antihypertensive medication will be clinically validated and refined through an innovative RCT across 4 sites in Europe.

The result is a clinical decision support tool that will give clinicians the ability to make an informed selection of whether the patient they are treating will best respond to the use of angiotensin inhibition, calcium antagonists, beta-blockers, or a range of other existing drugs with evidence-based for BP control. To ensure sustainability, the project will also develop a framework for the uptake of this tool in routine care for patients with hypertension across Europe and beyond.

HYPERMARKER will be implemented by a group of world-class scientists and clinicians from a diversity of disciplines who have collaborated multiple times and have a track record of leading key national and EU-funded initiatives to deliver high-impact results.

Topics

Who is involved

OrganisationCityCountryRole
Universitair Medisch Centrum UtrechtUtrechtNetherlandsCoordinator
European Heart Network AisblBruxelles / BrusselBelgiumParticipant
Collaborate Project Management GmbHMunchenGermanyParticipant
Universitaetsklinikum Hamburg-EppendorfHamburgGermanyParticipant
Fundacion Para La Investigacion Del Hospital Clinico De La Comunitat Valenciana, Fundacion InclivaValenciaSpainParticipant
Euretos B.v.UtrechtNetherlandsParticipant
Roche Diagnostics Nederland BVAlmereNetherlandsParticipant
Stichting Amsterdam UmcAmsterdamNetherlandsParticipant
Universiteit LeidenLeidenNetherlandsParticipant
Universiteit UtrechtUtrechtNetherlandsParticipant
Viduet Health BVBunnikNetherlandsParticipant
London School of Economics and Political ScienceLondonUnited KingdomAssociatedpartner
The University of BirminghamBirminghamUnited KingdomAssociatedpartner

Source: CORDIS, European Commission. Data of 5 Nov 2026, reused under the Commission's reuse policy. View on CORDIS · Grant DOI